{"nctId":"NCT03726879","briefTitle":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","startDateStruct":{"date":"2019-01-11","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":454,"armGroups":[{"label":"Atezolizumab +ddAC-PacHP","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: Doxorubicin","Drug: Cyclophosphamide","Drug: Paclitaxel","Drug: Trastuzumab","Drug: Pertuzumab","Drug: Trastuzumab Emtansine"]},{"label":"Placebo + ddAC-PacHP","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Doxorubicin","Drug: Cyclophosphamide","Drug: Paclitaxel","Drug: Trastuzumab","Drug: Pertuzumab","Drug: Trastuzumab Emtansine"]}],"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"]},{"name":"Placebo","otherNames":[]},{"name":"Doxorubicin","otherNames":["Adriamycin"]},{"name":"Cyclophosphamide","otherNames":["Cytoxan","Neosar"]},{"name":"Paclitaxel","otherNames":["Taxol"]},{"name":"Trastuzumab","otherNames":["Herceptin"]},{"name":"Pertuzumab","otherNames":["Perjeta"]},{"name":"Trastuzumab Emtansine","otherNames":["Kadcyla"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of HER2-positive breast cancer, and hormonal and PD-L1 status, as documented through central testing of a representative tumor tissue specimen\n* Primary breast tumor size of \\> 2 cm by any radiographic measurement\n* Stage at presentation: T2-T4, N1-N3, M0 as determined by AJCC staging system, 8th edition\n* Pathologic confirmation of nodal involvement with malignancy must be determined by fine needle aspiration or core-needle biopsy. Surgical excision of lymph nodes is not permitted.\n* Patients with multifocal tumors are eligible provided at least one focus is sampled and centrally confirmed as HER2-positive.\n* Patients with multicentric tumors are eligible provided all discrete lesions are sampled and centrally confirmed as HER2-positive.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Baseline LVEF \\>= 55% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans\n* Adequate hematologic and end-organ function obtained within 14 days prior to initiation of study treatment\n* For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm\n\nExclusion Criteria:\n\n* Prior history of invasive breast cancer\n* Stage IV (metastatic) breast cancer\n* Patients with synchronous bilateral invasive breast cancer\n* Prior systemic therapy for treatment of breast cancer\n* Previous therapy with anthracyclines or taxanes for any malignancy\n* Ulcerating or inflammatory breast cancer\n* Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes\n* Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of neoadjuvant therapy\n* History of other malignancy within 5 years prior to screening, with the exception of those patients who have a negligible risk of metastasis or death\n* Cardiopulmonary dysfunction\n* Dyspnea at rest\n* Active or history of autoimmune disease or immune deficiency\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab/placebo, 6 months after the final dose of doxorubicin, 12 months after the final dose of cyclophosphamide, 6 months after the final dose of paclitaxel, or 7 months after the final dose of trastuzumab, pertuzumab, or trastuzumab emtansine whichever occurs last\n\nExclusion Criteria Related to Trastuzumab Emtansine in the Adjuvant Setting:\n\n* Patients who achieved pCR\n* Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery\n* Unable to complete surgery with curative intent after conclusion of neoadjuvant systemic therapy\n* Patient discontinued treatment with trastuzumab because of toxicity during the neoadjuvant phase of the study\n* Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, or sclerosis cholangitis\n* Patients with Grade \\>=2 peripheral neuropathy\n* Prior treatment with trastuzumab emtansine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)","description":"pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer \\[AJCC\\] staging system, 8th edition). Treatment comparison was made using Cochran-Mantel-Haenszel test stratified by disease stage (T2 vs. T3-4) and hormone receptor status (estrogen receptor (ER) positive and/or progesterone receptor (PgR) positive vs. ER negative and PgR negative).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"72.5","spread":null}]}]}]},{"type":"PRIMARY","title":"pCR in the ITT Population","description":"pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer \\[AJCC\\] staging system, 8th edition). Treatment comparison was made using Cochran-Mantel-Haenszel test stratified by disease stage (T2 vs. T3-4) and hormone receptor status (ER positive and/or PgR positive vs. ER negative and PgR negative).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With pCR Based on Hormone Receptor Status","description":"pCR (ypT0/is ypN0) based upon hormone receptor status (estrogen receptor \\[ER\\]/progesterone receptor \\[PgR\\] positive or ER/PgR negative).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With pCR in the PD-L1-Negative Population","description":"pCR (ypT0/is ypN0) in the IC 0 Population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (EFS)","description":"EFS defined as the time from randomization to the first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death from any cause, whichever occurs first, in all patients and based upon hormone receptor status (ER/PgR positive or ER/PgR negative) and PD-L1 status (IC 0; IC 1/2/3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival (DFS)","description":"DFS defined as the time from surgery to the first documented disease recurrence or death from any cause, whichever occurs first, in all patients who undergo surgery and based upon PD-L1 status (IC 0; IC 1/2/3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS defined as the time from randomization to death from any cause in all participants and based upon PD-L1 status (IC 0; IC 1/2/3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Changes From Baseline in Function (Role, Physical)","description":"EORTC QLQ-C30 is a self-reported questionnaire that included functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), global health scale/quality of life (GHS/QOL) and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Questions 1-28 on the QLQ-C30 were on a 4-point scale (1=Not at All to 4=Very Much). Questions 29-30 (GHS scale) were on a 7-point scale (1=Very Poor to 7=Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.70","spread":"16.28"},{"groupId":"OG001","value":"90.85","spread":"20.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.06","spread":"23.02"},{"groupId":"OG001","value":"-9.83","spread":"23.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.88","spread":"26.20"},{"groupId":"OG001","value":"-15.15","spread":"22.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.27","spread":"27.04"},{"groupId":"OG001","value":"-17.98","spread":"25.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.08","spread":"28.21"},{"groupId":"OG001","value":"-19.79","spread":"26.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.70","spread":"25.46"},{"groupId":"OG001","value":"-18.60","spread":"25.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.21","spread":"25.50"},{"groupId":"OG001","value":"-16.67","spread":"26.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.25","spread":"26.48"},{"groupId":"OG001","value":"-17.79","spread":"26.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.82","spread":"26.70"},{"groupId":"OG001","value":"-26.24","spread":"31.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.48","spread":"22.31"},{"groupId":"OG001","value":"-15.15","spread":"26.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.42","spread":"23.77"},{"groupId":"OG001","value":"-15.24","spread":"26.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.30","spread":"24.26"},{"groupId":"OG001","value":"-15.42","spread":"25.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.68","spread":"24.00"},{"groupId":"OG001","value":"-15.88","spread":"22.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.24","spread":"23.69"},{"groupId":"OG001","value":"-14.55","spread":"24.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.34","spread":"21.11"},{"groupId":"OG001","value":"-15.43","spread":"27.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.04","spread":"25.18"},{"groupId":"OG001","value":"-18.10","spread":"29.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.02","spread":"25.06"},{"groupId":"OG001","value":"-17.16","spread":"23.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.17","spread":"23.24"},{"groupId":"OG001","value":"-14.65","spread":"25.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"16.67"},{"groupId":"OG001","value":"-10.42","spread":"21.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.78","spread":"25.46"},{"groupId":"OG001","value":"-25.00","spread":"9.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-33.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.74","spread":"11.60"},{"groupId":"OG001","value":"92.20","spread":"12.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.32","spread":"9.75"},{"groupId":"OG001","value":"-3.88","spread":"13.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.82","spread":"13.39"},{"groupId":"OG001","value":"-7.18","spread":"12.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.98","spread":"17.67"},{"groupId":"OG001","value":"-9.48","spread":"14.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.84","spread":"16.76"},{"groupId":"OG001","value":"-10.67","spread":"15.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.25","spread":"15.97"},{"groupId":"OG001","value":"-11.40","spread":"17.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.33","spread":"14.86"},{"groupId":"OG001","value":"-11.45","spread":"17.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.30","spread":"17.11"},{"groupId":"OG001","value":"-11.56","spread":"17.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.27","spread":"18.26"},{"groupId":"OG001","value":"-12.19","spread":"19.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.96","spread":"14.74"},{"groupId":"OG001","value":"-8.60","spread":"16.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.38","spread":"14.97"},{"groupId":"OG001","value":"-8.88","spread":"15.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.22","spread":"15.17"},{"groupId":"OG001","value":"-10.03","spread":"15.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.35","spread":"16.19"},{"groupId":"OG001","value":"-8.45","spread":"14.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.80","spread":"13.69"},{"groupId":"OG001","value":"-9.88","spread":"15.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.77","spread":"13.67"},{"groupId":"OG001","value":"-10.78","spread":"16.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.20","spread":"15.78"},{"groupId":"OG001","value":"-13.05","spread":"19.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.06","spread":"18.11"},{"groupId":"OG001","value":"-11.57","spread":"19.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"12.52"},{"groupId":"OG001","value":"-9.90","spread":"15.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"16.78"},{"groupId":"OG001","value":"-14.17","spread":"7.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"20.00"},{"groupId":"OG001","value":"-6.67","spread":"11.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"60.00","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Mean Changes From Baseline in Global Health Status","description":"EORTC QLQ-C30 is a self-reported questionnaire that included functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), GHS/QOL and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Questions 1-28 on the QLQ-C30 were on a 4-point scale (1=Not at All to 4=Very Much). Questions 29-30 (GHS scale) were on a 7-point scale (1=Very Poor to 7=Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.49","spread":"19.33"},{"groupId":"OG001","value":"76.79","spread":"19.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.28","spread":"19.70"},{"groupId":"OG001","value":"-6.31","spread":"19.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.96","spread":"22.16"},{"groupId":"OG001","value":"-8.33","spread":"20.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.67","spread":"22.47"},{"groupId":"OG001","value":"-10.88","spread":"21.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.14","spread":"23.76"},{"groupId":"OG001","value":"-12.63","spread":"23.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.33","spread":"22.10"},{"groupId":"OG001","value":"-9.99","spread":"20.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.47","spread":"19.81"},{"groupId":"OG001","value":"-10.52","spread":"21.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.72","spread":"22.45"},{"groupId":"OG001","value":"-10.86","spread":"22.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.89","spread":"21.89"},{"groupId":"OG001","value":"-7.14","spread":"23.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.51","spread":"22.97"},{"groupId":"OG001","value":"-5.21","spread":"21.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.07","spread":"22.31"},{"groupId":"OG001","value":"-6.75","spread":"21.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.20","spread":"21.47"},{"groupId":"OG001","value":"-6.01","spread":"20.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.02","spread":"21.10"},{"groupId":"OG001","value":"-5.05","spread":"20.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.29","spread":"21.75"},{"groupId":"OG001","value":"-7.80","spread":"22.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.95","spread":"21.71"},{"groupId":"OG001","value":"-6.03","spread":"20.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.96","spread":"22.08"},{"groupId":"OG001","value":"-9.41","spread":"24.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.90","spread":"21.64"},{"groupId":"OG001","value":"-5.15","spread":"21.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"19.55"},{"groupId":"OG001","value":"-3.03","spread":"16.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"8.33"},{"groupId":"OG001","value":"-7.29","spread":"15.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.89","spread":"12.73"},{"groupId":"OG001","value":"-31.94","spread":"37.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-16.67","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration (Cmax) of Atezolizumab","description":"Cmax is the maximum (or peak) concentration that a study drug achieves in the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":"122"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration (Cmin) of Atezolizumab","description":"Cmin is the minimum (or trough) concentration that a study drug achieves in the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":"40.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":"44.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":"51.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":"97.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":"101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":"114"}]}]}]},{"type":"SECONDARY","title":"Trough Concentration (Ctrough) for Pertuzumab and Trastuzumab in Serum","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":"40.7"},{"groupId":"OG001","value":"94.8","spread":"39.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7","spread":"58.4"},{"groupId":"OG001","value":"91.6","spread":"59.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":"29.1"},{"groupId":"OG001","value":"56.5","spread":"23.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":"32.7"},{"groupId":"OG001","value":"60.4","spread":"30.9"}]}]}]},{"type":"SECONDARY","title":"Cmax of Trastuzumab Emtansine in Serum","description":"Cmax is the maximum (or peak) concentration that a study drug achieves in the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":"29.0"},{"groupId":"OG001","value":"80.5","spread":"26.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"32.2"},{"groupId":"OG001","value":"82.0","spread":"37.2"}]}]}]},{"type":"SECONDARY","title":"Cmin of Trastuzumab Emtansine in Serum","description":"Cmin is the minimum (or trough) concentration that a study drug achieves in the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"5.09"},{"groupId":"OG001","value":"1.22","spread":"1.49"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) to Atezolizumab","description":"Participants were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants were considered to be treatment-emergent ADA-negative if they were ADA-negative or were missing data at baseline and all post-baseline samples were negative, or if they were ADA-positive at baseline but did not have any post-baseline samples with a titer that was at least 0.60 titer units greater than the titer of the baseline sample (treatment unaffected).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent ADAs to Trastuzumab","description":"Participants were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants were considered to be treatment-emergent ADA-negative if they were ADA-negative or were missing data at baseline and all post-baseline samples were negative, or if they were ADA-positive at baseline but did not have any post-baseline samples with a titer that was at least 0.60 titer units greater than the titer of the baseline sample (treatment unaffected).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent ADAs to Pertuzumab","description":"Participants were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants were considered to be treatment-emergent ADA-negative if they were ADA-negative or were missing data at baseline and all post-baseline samples were negative, or if they were ADA-positive at baseline but did not have any post-baseline samples with a titer that was at least 0.60 titer units greater than the titer of the baseline sample (treatment unaffected).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"214","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent ADAs to Trastuzumab Emtansine","description":"Participants were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants were considered to be treatment-emergent ADA-negative if they were ADA-negative or were missing data at baseline and all post-baseline samples were negative, or if they were ADA-positive at baseline but did not have any post-baseline samples with a titer that was at least 0.60 titer units greater than the titer of the baseline sample (treatment unaffected).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With pCR Based on PIK3CA Mutation Status","description":"pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer \\[AJCC\\] staging system, 8th edition).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"EFS Based on PIK3CA Mutation Status","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"DFS Based on PIK3CA Mutation Status","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Based on PIK3CA Mutation Status","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":226},"commonTop":["Alopecia","Diarrhoea","Nausea","Anaemia","Asthenia"]}}}